Kharchenko, Peter V
Silberstein, Lev
Scadden, David T
Article History
Received: 2 October 2013
Accepted: 28 March 2014
First Online: 18 May 2014
Competing interests
: D.T.S. is a shareholder in Fate Therapeutics and is a consultant for Fate Therapeutics, Hospira, GlaxoSmithKline and Bone Therapeutics. The remaining authors declare no competing financial interests.